Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
caused a devastating pandemic. Although most people infected with SARS-CoV-2 develop …

Background Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and
are effective disease-modifying treatments for several autoimmune diseases. Whether …

Abstract SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been
associated with substantial global morbidity and mortality. Despite a tropism that is largely …

Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

As of May 2022, there have been over 524 million confirmed cases of COVID-19 (10). The
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …

The four Janus kinase (JAK) proteins and seven signal transducer and activator of
transcription (STAT) transcription factors mediate intracellular signal transduction …

The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Summary Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown
efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) …